Immunic, Inc. (NASDAQ:IMUX) Stock Has Average Target Price of $35.43

Key Points

• Analysts remain broadly bullish: Immunic has a consensus “Buy” rating from 14 analysts, with an average 12-month price target of $35.43.
• Institutional ownership is significant: Hedge funds and other institutional investors own 51.82% of Immunic, with several firms recently initiating or increasing positions.
• The stock is under pressure: Shares opened at $7.34, down 2.3%, and remain well below their 12-month high of $17.43. Immunic reported quarterly EPS of -$0.80, beating estimates of -$1.16.

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the fourteen analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have given a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $35.43.

A number of equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research note on Saturday, October 10th. Roth Capital restated a "buy" rating on shares of Immunic in a research report on Tuesday, September 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunic in a report on Wednesday, August 26th. Wedbush reaffirmed an "outperform" rating and set a $45.00 price objective on shares of Immunic in a report on Thursday, September 10th. Finally, Zacks Research upgraded shares of Immunic from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, October 21st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CTC Alternative Strategies Ltd. purchased a new stake in shares of Immunic during the first quarter worth approximately $27,000. ADAR1 Capital Management LLC acquired a new position in Immunic in the 1st quarter valued at $33,000. China Universal Asset Management Co. Ltd. lifted its holdings in Immunic by 21.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company's stock valued at $69,000 after purchasing an additional 1,400 shares in the last quarter. Bank of America Corp DE lifted its holdings in Immunic by 80,724.2% in the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company's stock valued at $160,000 after purchasing an additional 143,689 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new position in Immunic in the 1st quarter valued at $187,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Trading Down 2.3%

Shares of IMUX stock opened at $7.34 on Tuesday. Immunic has a 12-month low of $5.06 and a 12-month high of $17.43. The business's 50 day moving average is $10.07 and its two-hundred day moving average is $11.46. The company has a market capitalization of $100.12 million, a P/E ratio of -1.68 and a beta of 1.45.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.36. On average, research analysts predict that Immunic will post -3.69 earnings per share for the current fiscal year.

About Immunic

Immunic, Inc NASDAQ: IMUX is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies.

Immunic's lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.